nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—gestational diabetes	0.729	1	CbGaD
Thalidomide—CYP2C19—Glyburide—gestational diabetes	0.0545	0.546	CbGbCtD
Thalidomide—CYP2C9—Glyburide—gestational diabetes	0.0453	0.454	CbGbCtD
Thalidomide—Pomalidomide—TNF—gestational diabetes	0.00516	1	CrCbGaD
Thalidomide—NFKB1—islet of Langerhans—gestational diabetes	0.00383	0.0774	CbGeAlD
Thalidomide—TNF—vagina—gestational diabetes	0.00356	0.072	CbGeAlD
Thalidomide—CRBN—islet of Langerhans—gestational diabetes	0.00321	0.0649	CbGeAlD
Thalidomide—CRBN—embryo—gestational diabetes	0.0031	0.0627	CbGeAlD
Thalidomide—Inappropriate antidiuretic hormone secretion—Glyburide—gestational diabetes	0.00279	0.0558	CcSEcCtD
Thalidomide—FGFR2—embryo—gestational diabetes	0.00278	0.0562	CbGeAlD
Thalidomide—NFKB1—uterus—gestational diabetes	0.0025	0.0505	CbGeAlD
Thalidomide—NFKB1—adipose tissue—gestational diabetes	0.00244	0.0494	CbGeAlD
Thalidomide—Cholestasis—Glyburide—gestational diabetes	0.00214	0.0427	CcSEcCtD
Thalidomide—CRBN—uterus—gestational diabetes	0.00209	0.0423	CbGeAlD
Thalidomide—CRBN—adipose tissue—gestational diabetes	0.00205	0.0414	CbGeAlD
Thalidomide—NFKB1—vagina—gestational diabetes	0.00203	0.041	CbGeAlD
Thalidomide—FGFR2—uterus—gestational diabetes	0.00187	0.0379	CbGeAlD
Thalidomide—NFKB1—head—gestational diabetes	0.00187	0.0379	CbGeAlD
Thalidomide—Jaundice cholestatic—Glyburide—gestational diabetes	0.00185	0.0369	CcSEcCtD
Thalidomide—FGFR2—adipose tissue—gestational diabetes	0.00183	0.0371	CbGeAlD
Thalidomide—Hyperbilirubinaemia—Glyburide—gestational diabetes	0.00179	0.0357	CcSEcCtD
Thalidomide—CRBN—vagina—gestational diabetes	0.0017	0.0344	CbGeAlD
Thalidomide—CRBN—head—gestational diabetes	0.00157	0.0318	CbGeAlD
Thalidomide—Aplastic anaemia—Glyburide—gestational diabetes	0.00152	0.0304	CcSEcCtD
Thalidomide—FGFR2—head—gestational diabetes	0.00141	0.0285	CbGeAlD
Thalidomide—FGFR2—FGFR2c ligand binding and activation—FGF2—gestational diabetes	0.00139	0.0207	CbGpPWpGaD
Thalidomide—NFKB1—Leptin signaling pathway—LEPR—gestational diabetes	0.00135	0.0202	CbGpPWpGaD
Thalidomide—Vascular purpura—Glyburide—gestational diabetes	0.00132	0.0263	CcSEcCtD
Thalidomide—Deafness—Glyburide—gestational diabetes	0.00132	0.0263	CcSEcCtD
Thalidomide—Renal failure acute—Glyburide—gestational diabetes	0.00128	0.0255	CcSEcCtD
Thalidomide—Visual disturbance—Glyburide—gestational diabetes	0.00124	0.0248	CcSEcCtD
Thalidomide—Dermatitis bullous—Glyburide—gestational diabetes	0.00123	0.0246	CcSEcCtD
Thalidomide—Purpura—Glyburide—gestational diabetes	0.00122	0.0244	CcSEcCtD
Thalidomide—Arthritis—Glyburide—gestational diabetes	0.00121	0.0242	CcSEcCtD
Thalidomide—Hypoglycaemia—Glyburide—gestational diabetes	0.00121	0.0241	CcSEcCtD
Thalidomide—Hyponatraemia—Glyburide—gestational diabetes	0.00118	0.0236	CcSEcCtD
Thalidomide—Diplopia—Glyburide—gestational diabetes	0.00118	0.0235	CcSEcCtD
Thalidomide—FGFR2—Activated point mutants of FGFR2—FGF2—gestational diabetes	0.00112	0.0167	CbGpPWpGaD
Thalidomide—Abdominal distension—Glyburide—gestational diabetes	0.00103	0.0205	CcSEcCtD
Thalidomide—CYP3A5—islet of Langerhans—gestational diabetes	0.00102	0.0206	CbGeAlD
Thalidomide—Eosinophilia—Glyburide—gestational diabetes	0.00101	0.0201	CcSEcCtD
Thalidomide—Pancreatitis—Glyburide—gestational diabetes	0.000999	0.0199	CcSEcCtD
Thalidomide—Pancytopenia—Glyburide—gestational diabetes	0.000968	0.0193	CcSEcCtD
Thalidomide—TNF—Transcription factor regulation in adipogenesis—LEP—gestational diabetes	0.000962	0.0144	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—RETN—gestational diabetes	0.000954	0.0143	CbGpPWpGaD
Thalidomide—Photosensitivity reaction—Glyburide—gestational diabetes	0.00093	0.0186	CcSEcCtD
Thalidomide—FGFR2—FGFR ligand binding and activation—FGF2—gestational diabetes	0.000878	0.0131	CbGpPWpGaD
Thalidomide—PTGS2—islet of Langerhans—gestational diabetes	0.000873	0.0177	CbGeAlD
Thalidomide—FGFR2—Angiogenesis—FGF2—gestational diabetes	0.000849	0.0127	CbGpPWpGaD
Thalidomide—Agranulocytosis—Glyburide—gestational diabetes	0.000848	0.0169	CcSEcCtD
Thalidomide—PTGS2—embryo—gestational diabetes	0.000845	0.0171	CbGeAlD
Thalidomide—Hepatitis—Glyburide—gestational diabetes	0.000816	0.0163	CcSEcCtD
Thalidomide—Visual impairment—Glyburide—gestational diabetes	0.000786	0.0157	CcSEcCtD
Thalidomide—Eye disorder—Glyburide—gestational diabetes	0.000762	0.0152	CcSEcCtD
Thalidomide—NFKB1—Transcriptional regulation of white adipocyte differentiation—ADIPOQ—gestational diabetes	0.000746	0.0112	CbGpPWpGaD
Thalidomide—FGFR2—SHC-mediated cascade—FGF2—gestational diabetes	0.00073	0.0109	CbGpPWpGaD
Thalidomide—Alopecia—Glyburide—gestational diabetes	0.000721	0.0144	CcSEcCtD
Thalidomide—CYP2E1—Vitamin A and Carotenoid Metabolism—RBP4—gestational diabetes	0.000719	0.0107	CbGpPWpGaD
Thalidomide—Malnutrition—Glyburide—gestational diabetes	0.00071	0.0142	CcSEcCtD
Thalidomide—CYP2C19—vagina—gestational diabetes	0.000684	0.0138	CbGeAlD
Thalidomide—CYP1A1—uterus—gestational diabetes	0.000678	0.0137	CbGeAlD
Thalidomide—Vision blurred—Glyburide—gestational diabetes	0.000669	0.0134	CcSEcCtD
Thalidomide—Tremor—Glyburide—gestational diabetes	0.000665	0.0133	CcSEcCtD
Thalidomide—CYP1A1—adipose tissue—gestational diabetes	0.000663	0.0134	CbGeAlD
Thalidomide—Anaemia—Glyburide—gestational diabetes	0.000656	0.0131	CcSEcCtD
Thalidomide—Angioedema—Glyburide—gestational diabetes	0.000649	0.013	CcSEcCtD
Thalidomide—CYP3A5—adipose tissue—gestational diabetes	0.000649	0.0131	CbGeAlD
Thalidomide—Leukopenia—Glyburide—gestational diabetes	0.000635	0.0127	CcSEcCtD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—MBL2—gestational diabetes	0.000629	0.0094	CbGpPWpGaD
Thalidomide—Convulsion—Glyburide—gestational diabetes	0.000615	0.0123	CcSEcCtD
Thalidomide—Arthralgia—Glyburide—gestational diabetes	0.000604	0.0121	CcSEcCtD
Thalidomide—Myalgia—Glyburide—gestational diabetes	0.000604	0.0121	CcSEcCtD
Thalidomide—PTGS1—uterus—gestational diabetes	0.000596	0.0121	CbGeAlD
Thalidomide—PTGS1—Biological oxidations—GGCT—gestational diabetes	0.000594	0.00888	CbGpPWpGaD
Thalidomide—Confusional state—Glyburide—gestational diabetes	0.000584	0.0117	CcSEcCtD
Thalidomide—PTGS1—adipose tissue—gestational diabetes	0.000583	0.0118	CbGeAlD
Thalidomide—Oedema—Glyburide—gestational diabetes	0.000579	0.0116	CcSEcCtD
Thalidomide—Shock—Glyburide—gestational diabetes	0.00057	0.0114	CcSEcCtD
Thalidomide—PTGS2—uterus—gestational diabetes	0.000569	0.0115	CbGeAlD
Thalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—ADIPOQ—gestational diabetes	0.000568	0.0085	CbGpPWpGaD
Thalidomide—Nervous system disorder—Glyburide—gestational diabetes	0.000568	0.0113	CcSEcCtD
Thalidomide—Thrombocytopenia—Glyburide—gestational diabetes	0.000567	0.0113	CcSEcCtD
Thalidomide—FGFR2—Negative regulation of FGFR signaling—FGF2—gestational diabetes	0.000564	0.00844	CbGpPWpGaD
Thalidomide—NFKB1—Canonical NF-kappaB pathway—TNF—gestational diabetes	0.000564	0.00843	CbGpPWpGaD
Thalidomide—NFKB1—EBV LMP1 signaling—TNF—gestational diabetes	0.000564	0.00843	CbGpPWpGaD
Thalidomide—Hyperhidrosis—Glyburide—gestational diabetes	0.00056	0.0112	CcSEcCtD
Thalidomide—PTGS2—adipose tissue—gestational diabetes	0.000557	0.0113	CbGeAlD
Thalidomide—Anorexia—Glyburide—gestational diabetes	0.000552	0.011	CcSEcCtD
Thalidomide—CYP1A1—vagina—gestational diabetes	0.000551	0.0112	CbGeAlD
Thalidomide—Hypotension—Glyburide—gestational diabetes	0.000541	0.0108	CcSEcCtD
Thalidomide—CYP3A5—vagina—gestational diabetes	0.000539	0.0109	CbGeAlD
Thalidomide—Musculoskeletal discomfort—Glyburide—gestational diabetes	0.000528	0.0105	CcSEcCtD
Thalidomide—FGFR2—FRS2-mediated cascade—FGF2—gestational diabetes	0.000523	0.00782	CbGpPWpGaD
Thalidomide—Paraesthesia—Glyburide—gestational diabetes	0.00052	0.0104	CcSEcCtD
Thalidomide—Dyspnoea—Glyburide—gestational diabetes	0.000517	0.0103	CcSEcCtD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—GCK—gestational diabetes	0.000515	0.0077	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR mutants—FGF2—gestational diabetes	0.000513	0.00768	CbGpPWpGaD
Thalidomide—Dyspepsia—Glyburide—gestational diabetes	0.00051	0.0102	CcSEcCtD
Thalidomide—CYP1A1—head—gestational diabetes	0.000509	0.0103	CbGeAlD
Thalidomide—Decreased appetite—Glyburide—gestational diabetes	0.000504	0.0101	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Glyburide—gestational diabetes	0.0005	0.00999	CcSEcCtD
Thalidomide—NFKB1—Angiopoietin receptor Tie2-mediated signaling—FGF2—gestational diabetes	0.000497	0.00744	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—GCK—gestational diabetes	0.000485	0.00726	CbGpPWpGaD
Thalidomide—PTGS1—vagina—gestational diabetes	0.000484	0.0098	CbGeAlD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—MBL2—gestational diabetes	0.000479	0.00716	CbGpPWpGaD
Thalidomide—Feeling abnormal—Glyburide—gestational diabetes	0.000477	0.00953	CcSEcCtD
Thalidomide—Gastrointestinal pain—Glyburide—gestational diabetes	0.000474	0.00946	CcSEcCtD
Thalidomide—NFKB1—Leptin signaling pathway—LEP—gestational diabetes	0.000473	0.00708	CbGpPWpGaD
Thalidomide—CYP2E1—head—gestational diabetes	0.000464	0.0094	CbGeAlD
Thalidomide—NFKB1—Transcriptional regulation of white adipocyte differentiation—LEP—gestational diabetes	0.000463	0.00693	CbGpPWpGaD
Thalidomide—PTGS2—vagina—gestational diabetes	0.000463	0.00937	CbGeAlD
Thalidomide—NFKB1—Cardiac Hypertrophic Response—FGF2—gestational diabetes	0.000461	0.00689	CbGpPWpGaD
Thalidomide—Urticaria—Glyburide—gestational diabetes	0.00046	0.00919	CcSEcCtD
Thalidomide—Abdominal pain—Glyburide—gestational diabetes	0.000458	0.00914	CcSEcCtD
Thalidomide—TNF—Adipogenesis—NAMPT—gestational diabetes	0.000457	0.00683	CbGpPWpGaD
Thalidomide—CYP1A2—Phase II conjugation—GGCT—gestational diabetes	0.000456	0.00682	CbGpPWpGaD
Thalidomide—PTGS1—head—gestational diabetes	0.000447	0.00905	CbGeAlD
Thalidomide—CYP2E1—Biological oxidations—GGCT—gestational diabetes	0.000444	0.00664	CbGpPWpGaD
Thalidomide—CYP2E1—Tryptophan metabolism—CYP19A1—gestational diabetes	0.000444	0.00664	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—GGCT—gestational diabetes	0.000443	0.00663	CbGpPWpGaD
Thalidomide—FGFR2—Cardiac Hypertrophic Response—FGF2—gestational diabetes	0.000437	0.00654	CbGpPWpGaD
Thalidomide—NFKB1—amb2 Integrin signaling—TNF—gestational diabetes	0.000433	0.00647	CbGpPWpGaD
Thalidomide—FGFR2—Phospholipase C-mediated cascade—FGF2—gestational diabetes	0.000431	0.00645	CbGpPWpGaD
Thalidomide—PTGS2—head—gestational diabetes	0.000428	0.00865	CbGeAlD
Thalidomide—Hypersensitivity—Glyburide—gestational diabetes	0.000427	0.00852	CcSEcCtD
Thalidomide—NFKB1—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—gestational diabetes	0.000422	0.00631	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—GGCT—gestational diabetes	0.000419	0.00626	CbGpPWpGaD
Thalidomide—CYP1A1—Tryptophan metabolism—CYP19A1—gestational diabetes	0.000418	0.00626	CbGpPWpGaD
Thalidomide—Asthenia—Glyburide—gestational diabetes	0.000416	0.0083	CcSEcCtD
Thalidomide—Pruritus—Glyburide—gestational diabetes	0.00041	0.00818	CcSEcCtD
Thalidomide—Diarrhoea—Glyburide—gestational diabetes	0.000396	0.00791	CcSEcCtD
Thalidomide—TNF—SIDS Susceptibility Pathways—GCK—gestational diabetes	0.000392	0.00587	CbGpPWpGaD
Thalidomide—PTGS1—Overview of nanoparticle effects—TNF—gestational diabetes	0.00039	0.00583	CbGpPWpGaD
Thalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—NAMPT—gestational diabetes	0.00039	0.00583	CbGpPWpGaD
Thalidomide—PTGS1—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	0.000389	0.00582	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—CYP19A1—gestational diabetes	0.000387	0.00578	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—TNF—gestational diabetes	0.000385	0.00576	CbGpPWpGaD
Thalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—FGF2—gestational diabetes	0.000379	0.00567	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—AR—gestational diabetes	0.000376	0.00562	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—ADIPOQ—gestational diabetes	0.000374	0.00559	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—GCK—gestational diabetes	0.00037	0.00553	CbGpPWpGaD
Thalidomide—FGFR2—PI3K Cascade—FGF2—gestational diabetes	0.000369	0.00552	CbGpPWpGaD
Thalidomide—Vomiting—Glyburide—gestational diabetes	0.000368	0.00736	CcSEcCtD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—AR—gestational diabetes	0.000366	0.00548	CbGpPWpGaD
Thalidomide—Rash—Glyburide—gestational diabetes	0.000365	0.00729	CcSEcCtD
Thalidomide—Dermatitis—Glyburide—gestational diabetes	0.000365	0.00729	CcSEcCtD
Thalidomide—Headache—Glyburide—gestational diabetes	0.000363	0.00725	CcSEcCtD
Thalidomide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	0.000359	0.00537	CbGpPWpGaD
Thalidomide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	0.000358	0.00535	CbGpPWpGaD
Thalidomide—CYP2E1—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	0.000354	0.00529	CbGpPWpGaD
Thalidomide—CYP3A5—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	0.000353	0.00528	CbGpPWpGaD
Thalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—LEP—gestational diabetes	0.000353	0.00528	CbGpPWpGaD
Thalidomide—TNF—Cardiac Hypertrophic Response—FGF2—gestational diabetes	0.000351	0.00525	CbGpPWpGaD
Thalidomide—NFKB1—TWEAK Signaling Pathway—TNF—gestational diabetes	0.000348	0.00521	CbGpPWpGaD
Thalidomide—Nausea—Glyburide—gestational diabetes	0.000344	0.00687	CcSEcCtD
Thalidomide—CYP2C19—Biological oxidations—GGCT—gestational diabetes	0.000343	0.00512	CbGpPWpGaD
Thalidomide—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	0.000338	0.00506	CbGpPWpGaD
Thalidomide—CYP1A1—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	0.000334	0.00499	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—FGF2—gestational diabetes	0.000328	0.00491	CbGpPWpGaD
Thalidomide—NFKB1—TNF receptor signaling pathway —TNF—gestational diabetes	0.000324	0.00484	CbGpPWpGaD
Thalidomide—NFKB1—Aryl Hydrocarbon Receptor—TNF—gestational diabetes	0.000324	0.00484	CbGpPWpGaD
Thalidomide—NFKB1—Ceramide signaling pathway—TNF—gestational diabetes	0.000313	0.00468	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—GGCT—gestational diabetes	0.000312	0.00467	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—FGF2—gestational diabetes	0.000312	0.00466	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—AR—gestational diabetes	0.000312	0.00466	CbGpPWpGaD
Thalidomide—PTGS2—Overview of nanoparticle effects—TNF—gestational diabetes	0.000309	0.00463	CbGpPWpGaD
Thalidomide—FGFR2—IRS-mediated signalling—FGF2—gestational diabetes	0.000309	0.00462	CbGpPWpGaD
Thalidomide—FGFR2—Constitutive PI3K/AKT Signaling in Cancer—FGF2—gestational diabetes	0.000306	0.00457	CbGpPWpGaD
Thalidomide—NFKB1—Angiopoietin receptor Tie2-mediated signaling—TNF—gestational diabetes	0.000303	0.00453	CbGpPWpGaD
Thalidomide—FGFR2—IRS-related events—FGF2—gestational diabetes	0.0003	0.00449	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—TNF—gestational diabetes	0.000298	0.00446	CbGpPWpGaD
Thalidomide—FGFR2—IRS-related events triggered by IGF1R—FGF2—gestational diabetes	0.000297	0.00445	CbGpPWpGaD
Thalidomide—CYP2E1—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	0.000291	0.00435	CbGpPWpGaD
Thalidomide—CYP3A5—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	0.00029	0.00434	CbGpPWpGaD
Thalidomide—FGFR2—IGF1R signaling cascade—FGF2—gestational diabetes	0.00029	0.00433	CbGpPWpGaD
Thalidomide—FGFR2—Insulin receptor signalling cascade—FGF2—gestational diabetes	0.00029	0.00433	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—gestational diabetes	0.000289	0.00432	CbGpPWpGaD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—TNF—gestational diabetes	0.000285	0.00426	CbGpPWpGaD
Thalidomide—NFKB1—Neural Crest Differentiation—FGF2—gestational diabetes	0.000283	0.00424	CbGpPWpGaD
Thalidomide—NFKB1—Cardiac Hypertrophic Response—TNF—gestational diabetes	0.000281	0.0042	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—AR—gestational diabetes	0.000279	0.00417	CbGpPWpGaD
Thalidomide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	0.000277	0.00414	CbGpPWpGaD
Thalidomide—FGFR2—PI-3K cascade—FGF2—gestational diabetes	0.000275	0.00412	CbGpPWpGaD
Thalidomide—CYP1A1—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	0.000274	0.0041	CbGpPWpGaD
Thalidomide—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	0.000273	0.00408	CbGpPWpGaD
Thalidomide—FGFR2—PI3K/AKT activation—FGF2—gestational diabetes	0.000269	0.00402	CbGpPWpGaD
Thalidomide—FGFR2—Neural Crest Differentiation—FGF2—gestational diabetes	0.000269	0.00402	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—GGCT—gestational diabetes	0.000267	0.00399	CbGpPWpGaD
Thalidomide—FGFR2—GAB1 signalosome—FGF2—gestational diabetes	0.000267	0.00399	CbGpPWpGaD
Thalidomide—CYP1A2—Tryptophan metabolism—CYP19A1—gestational diabetes	0.000267	0.00399	CbGpPWpGaD
Thalidomide—FGFR2—Cardiac Hypertrophic Response—TNF—gestational diabetes	0.000266	0.00398	CbGpPWpGaD
Thalidomide—FGFR2—Role of LAT2/NTAL/LAB on calcium mobilization—FGF2—gestational diabetes	0.000261	0.0039	CbGpPWpGaD
Thalidomide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	0.000252	0.00377	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—LEP—gestational diabetes	0.000251	0.00375	CbGpPWpGaD
Thalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—FGF2—gestational diabetes	0.00025	0.00374	CbGpPWpGaD
Thalidomide—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	0.000249	0.00372	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—TNF—gestational diabetes	0.000243	0.00363	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by Insulin receptor—FGF2—gestational diabetes	0.000241	0.0036	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—AR—gestational diabetes	0.000237	0.00355	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—LEP—gestational diabetes	0.000232	0.00347	CbGpPWpGaD
Thalidomide—NFKB1—Signaling events mediated by HDAC Class I—TNF—gestational diabetes	0.000231	0.00346	CbGpPWpGaD
Thalidomide—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	0.000224	0.00336	CbGpPWpGaD
Thalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	0.000216	0.00323	CbGpPWpGaD
Thalidomide—NFKB1—Transcriptional regulation of white adipocyte differentiation—TNF—gestational diabetes	0.000214	0.00321	CbGpPWpGaD
Thalidomide—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	0.000213	0.00318	CbGpPWpGaD
Thalidomide—PTGS1—Biological oxidations—CYP19A1—gestational diabetes	0.000207	0.00309	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—FGF2—gestational diabetes	0.000206	0.00308	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—GCK—gestational diabetes	0.000205	0.00306	CbGpPWpGaD
Thalidomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	0.000205	0.00306	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—MBL2—gestational diabetes	0.000201	0.00301	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—TNF—gestational diabetes	0.0002	0.00299	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—TNF—gestational diabetes	0.0002	0.00299	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—FGF2—gestational diabetes	0.000197	0.00295	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—FGF2—gestational diabetes	0.000197	0.00295	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—FGF2—gestational diabetes	0.000194	0.0029	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—TNF—gestational diabetes	0.000193	0.00288	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—MBL2—gestational diabetes	0.000191	0.00286	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—TNF—gestational diabetes	0.00019	0.00284	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—FGF2—gestational diabetes	0.00019	0.00283	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—TNF—gestational diabetes	0.000186	0.00278	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—FGF2—gestational diabetes	0.000185	0.00277	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—FGF2—gestational diabetes	0.000184	0.00276	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—FGF2—gestational diabetes	0.000183	0.00274	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—FGF2—gestational diabetes	0.000182	0.00273	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—FGF2—gestational diabetes	0.000181	0.00271	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—FGF2—gestational diabetes	0.00018	0.00269	CbGpPWpGaD
Thalidomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	0.000175	0.00261	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—FGF2—gestational diabetes	0.000172	0.00257	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—FGF2—gestational diabetes	0.000172	0.00257	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—FGF2—gestational diabetes	0.000172	0.00257	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—TNF—gestational diabetes	0.000171	0.00256	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—FGF2—gestational diabetes	0.00017	0.00255	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—FGF2—gestational diabetes	0.00017	0.00254	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—ADIPOQ—gestational diabetes	0.000169	0.00252	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—FGF2—gestational diabetes	0.000169	0.00252	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—FGF2—gestational diabetes	0.000168	0.00251	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—FGF2—gestational diabetes	0.000167	0.0025	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—FGF2—gestational diabetes	0.000159	0.00238	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—GCK—gestational diabetes	0.000156	0.00233	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—LEP—gestational diabetes	0.000155	0.00232	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—CYP19A1—gestational diabetes	0.000154	0.00231	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—CYP19A1—gestational diabetes	0.000154	0.00231	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—gestational diabetes	0.000153	0.00228	CbGpPWpGaD
Thalidomide—CYP2E1—Metapathway biotransformation—CYP19A1—gestational diabetes	0.000152	0.00228	CbGpPWpGaD
Thalidomide—CYP3A5—Metapathway biotransformation—CYP19A1—gestational diabetes	0.000152	0.00227	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—FGF2—gestational diabetes	0.000152	0.00227	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AR—gestational diabetes	0.000147	0.0022	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—CYP19A1—gestational diabetes	0.000146	0.00218	CbGpPWpGaD
Thalidomide—CYP1A1—Metapathway biotransformation—CYP19A1—gestational diabetes	0.000144	0.00215	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—gestational diabetes	0.000143	0.00213	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—TNF—gestational diabetes	0.000135	0.00202	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—gestational diabetes	0.000135	0.00202	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—TNF—gestational diabetes	0.000134	0.002	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—FGF2—gestational diabetes	0.00013	0.00194	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—ADIPOQ—gestational diabetes	0.000128	0.00192	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—FGF2—gestational diabetes	0.000123	0.00184	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—TNF—gestational diabetes	0.000122	0.00182	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—CYP19A1—gestational diabetes	0.000119	0.00178	CbGpPWpGaD
Thalidomide—CYP2C19—Metapathway biotransformation—CYP19A1—gestational diabetes	0.000118	0.00176	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MBL2—gestational diabetes	0.000117	0.00175	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—FGF2—gestational diabetes	0.000117	0.00175	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TNF—gestational diabetes	0.000115	0.00172	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—TNF—gestational diabetes	0.000114	0.00171	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MBL2—gestational diabetes	0.000111	0.00166	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—CYP19A1—gestational diabetes	0.000109	0.00163	CbGpPWpGaD
Thalidomide—CYP2C9—Metapathway biotransformation—CYP19A1—gestational diabetes	0.000107	0.0016	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—LEP—gestational diabetes	0.000105	0.00157	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TNF—gestational diabetes	0.000104	0.00155	CbGpPWpGaD
Thalidomide—FGFR2—Disease—RBP4—gestational diabetes	0.000104	0.00155	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GGCT—gestational diabetes	0.000102	0.00152	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LEPR—gestational diabetes	9.92e-05	0.00148	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LEPR—gestational diabetes	9.41e-05	0.00141	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NAMPT—gestational diabetes	9.29e-05	0.00139	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—CYP19A1—gestational diabetes	9.29e-05	0.00139	CbGpPWpGaD
Thalidomide—FGFR2—Disease—GCK—gestational diabetes	9.23e-05	0.00138	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—CYP19A1—gestational diabetes	9.16e-05	0.00137	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—TNF—gestational diabetes	9.08e-05	0.00136	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GLS2—gestational diabetes	8.88e-05	0.00133	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—gestational diabetes	8.63e-05	0.00129	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—gestational diabetes	8.63e-05	0.00129	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GGCT—gestational diabetes	8.07e-05	0.00121	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FGF2—gestational diabetes	8.02e-05	0.0012	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—LEP—gestational diabetes	7.98e-05	0.00119	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—FGF2—gestational diabetes	7.96e-05	0.00119	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—gestational diabetes	7.94e-05	0.00119	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MTNR1B—gestational diabetes	7.84e-05	0.00117	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RBP4—gestational diabetes	7.64e-05	0.00114	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GGCT—gestational diabetes	7.59e-05	0.00114	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GGCT—gestational diabetes	7.58e-05	0.00113	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MTNR1B—gestational diabetes	7.44e-05	0.00111	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RBP4—gestational diabetes	7.25e-05	0.00108	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—gestational diabetes	7.18e-05	0.00107	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GGCT—gestational diabetes	7.16e-05	0.00107	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GLS2—gestational diabetes	7.05e-05	0.00105	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—FGF2—gestational diabetes	7.03e-05	0.00105	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—FGF2—gestational diabetes	6.75e-05	0.00101	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—FGF2—gestational diabetes	6.67e-05	0.000997	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GLS2—gestational diabetes	6.64e-05	0.000992	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GLS2—gestational diabetes	6.62e-05	0.00099	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—FGF2—gestational diabetes	6.4e-05	0.000958	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—gestational diabetes	6.3e-05	0.000942	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GLS2—gestational diabetes	6.26e-05	0.000936	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—FGF2—gestational diabetes	6.06e-05	0.000907	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GGCT—gestational diabetes	5.86e-05	0.000876	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—gestational diabetes	5.59e-05	0.000836	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GGCT—gestational diabetes	5.34e-05	0.000799	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RBP4—gestational diabetes	5.14e-05	0.000769	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GLS2—gestational diabetes	5.12e-05	0.000766	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—gestational diabetes	4.88e-05	0.00073	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NAMPT—gestational diabetes	4.87e-05	0.000728	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—gestational diabetes	4.85e-05	0.000725	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GCK—gestational diabetes	4.84e-05	0.000723	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GLS2—gestational diabetes	4.67e-05	0.000698	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NAMPT—gestational diabetes	4.61e-05	0.00069	CbGpPWpGaD
Thalidomide—PTGS2—Disease—GCK—gestational diabetes	4.58e-05	0.000685	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—gestational diabetes	4.58e-05	0.000684	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GGCT—gestational diabetes	4.56e-05	0.000683	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—gestational diabetes	4.17e-05	0.000624	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FGF2—gestational diabetes	4.09e-05	0.000612	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GLS2—gestational diabetes	3.99e-05	0.000597	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FGF2—gestational diabetes	3.88e-05	0.000581	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NAMPT—gestational diabetes	3.86e-05	0.000578	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GCK—gestational diabetes	3.84e-05	0.000574	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NAMPT—gestational diabetes	3.64e-05	0.000544	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NAMPT—gestational diabetes	3.63e-05	0.000543	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GCK—gestational diabetes	3.61e-05	0.00054	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GCK—gestational diabetes	3.61e-05	0.000539	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FGF2—gestational diabetes	3.59e-05	0.000536	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—gestational diabetes	3.57e-05	0.000533	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP19A1—gestational diabetes	3.54e-05	0.000529	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LEP—gestational diabetes	3.48e-05	0.000521	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NAMPT—gestational diabetes	3.43e-05	0.000513	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GCK—gestational diabetes	3.41e-05	0.000509	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LEP—gestational diabetes	3.31e-05	0.000494	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP19A1—gestational diabetes	2.81e-05	0.00042	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NAMPT—gestational diabetes	2.81e-05	0.00042	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GCK—gestational diabetes	2.79e-05	0.000417	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGF2—gestational diabetes	2.65e-05	0.000396	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP19A1—gestational diabetes	2.64e-05	0.000395	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP19A1—gestational diabetes	2.64e-05	0.000394	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NAMPT—gestational diabetes	2.56e-05	0.000383	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GCK—gestational diabetes	2.54e-05	0.00038	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGF2—gestational diabetes	2.51e-05	0.000376	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP19A1—gestational diabetes	2.49e-05	0.000373	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NAMPT—gestational diabetes	2.19e-05	0.000327	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GCK—gestational diabetes	2.17e-05	0.000325	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP19A1—gestational diabetes	2.04e-05	0.000305	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP19A1—gestational diabetes	1.86e-05	0.000278	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGF2—gestational diabetes	1.78e-05	0.000266	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP19A1—gestational diabetes	1.59e-05	0.000238	CbGpPWpGaD
